Fig. 4From: Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyHematologic parameters: a median hemoglobin levels, b platelet counts, and c ANCs over time. Includes patients from the safety-evaluable population. Error bars represent 25th and 75th percentiles. Dotted lines represent the median value at baseline. ANC, absolute neutrophil count; BL, baselineBack to article page